ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mesenchymal stem cell treatment for COVID-19

Xu, Ruonan*; Feng, Zhiqian; Wang, Fu-Sheng*南方医科大学; 5
EBioMedicine2022-3DOI: 10.1016/j.ebiom.2022.103920
32被引6阅读
引用收藏
分享

摘要

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection. Among them, less than 7% of infected individuals develop severe or critical illness. Mass vaccination has been carried out, but reinfection and vaccine breakthrough cases still occur. Besides supportive and antiviral medications, much attention has been paid in immunotherapies that aim at reducing pathological changes in the lungs. Mesenchymal stem cells (MSCs) is used as an option because of their immunomodulatory, anti-inflammatory, and regenerative properties. As of January 16, 2022, when ClinicalTrials.gov was searched for "Mesenchymal stem cells and COVID-19, " over 80 clinical trials were registered. MSC therapy was found to be safe and some effective in preclinical and clinical studies. Here, we summarize the major pathological characteristics of COVID-19 and provide scientific and rational evidence for the safety and possi-ble effectiveness of MSCs in COVID-19 treatment.

学科与关键词

关键词
COVID-19Mesenchymal stem cellImmune therapyLung injury
相关
加载中…
  • Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS
    Xu, Zhiheng; Huang, Yongbo; Zhou, Jianmeng; Deng, Xiumei; He, Weiqun; Liu, Xiaoqing; Li, Yimin; Zhong, Nanshan*; Sang, Ling*Frontiers in Immunology, 2021, 12: 738697.被引 13
  • Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review
    Huang, Xiaohua; Tan, Xin; Xie, Xiuwen; Jiang, Tingshu; Xiao, Yang; Liu, Zenghui*Frontiers in Immunology, 2024, 15: 1321236.
  • Stem cell-based therapy for COVID-19
    Chen, Xiaomei; Liu, Bowen; Li, Chao; Wang, Yulian; Geng, Suxia; Du, Xin; Weng, Jianyu; Lai, Peilong*International Immunopharmacology, 2023, 124: 110890.
查看全部 →

发表信息

论文状态
公开发表
期刊
EBioMedicine
发表日期
2022-03
卷期
第 77 卷
页码
103920
DOI
10.1016/j.ebiom.2022.103920
期刊等级
1区
成果收录
SCIE
资助标注
Innovative Research Group Project of the National Natural Science Foundation of China [81721002]; National Key Research and Development Program of China [2017YFA0105700]

作者

  • X

    Xu, Ruonan (通讯) (第一作者)

    5 · peoples liberat army gen hosp

  • F

    Feng, Zhiqian

    2 · southern med univ

查看全部 3 位作者收起作者
  • W

    Wang, Fu-Sheng (通讯)

    5 · peoples liberat army gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417